Lannett Company - News Releases http://lannett.investorroom.com/ Lannett To Present At The Jefferies 2017 London Healthcare Conference On November 15 http://lannett.investorroom.com/2017-11-09-Lannett-To-Present-At-The-Jefferies-2017-London-Healthcare-Conference-On-November-15 Thu, 09 Nov 2017 06:56:00 -0500 http://lannett.investorroom.com/2017-11-09-Lannett-To-Present-At-The-Jefferies-2017-London-Healthcare-Conference-On-November-15 Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance http://lannett.investorroom.com/2017-11-06-Lannett-Reports-Solid-Fiscal-2018-First-Quarter-Financial-Results-Significantly-Increases-Fiscal-2018-Guidance Mon, 06 Nov 2017 16:15:00 -0500 http://lannett.investorroom.com/2017-11-06-Lannett-Reports-Solid-Fiscal-2018-First-Quarter-Financial-Results-Significantly-Increases-Fiscal-2018-Guidance Lannett Comments On Amended Civil Complaint http://lannett.investorroom.com/2017-11-01-Lannett-Comments-On-Amended-Civil-Complaint Wed, 01 Nov 2017 06:53:00 -0400 http://lannett.investorroom.com/2017-11-01-Lannett-Comments-On-Amended-Civil-Complaint Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid® http://lannett.investorroom.com/2017-10-30-Lannett-And-Celgene-Enter-Into-Settlement-And-License-Agreement-Related-To-Thalomid-R Mon, 30 Oct 2017 06:52:00 -0400 http://lannett.investorroom.com/2017-10-30-Lannett-And-Celgene-Enter-Into-Settlement-And-License-Agreement-Related-To-Thalomid-R Lannett To Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call On Monday, November 6 http://lannett.investorroom.com/2017-10-26-Lannett-To-Report-Fiscal-2018-First-Quarter-Financial-Results-Host-Conference-Call-On-Monday-November-6 Thu, 26 Oct 2017 06:51:00 -0400 http://lannett.investorroom.com/2017-10-26-Lannett-To-Report-Fiscal-2018-First-Quarter-Financial-Results-Host-Conference-Call-On-Monday-November-6 Lannett Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules USP, One Each For Full Prescription And OTC http://lannett.investorroom.com/2017-10-02-Lannett-Receives-Two-FDA-Approvals-For-Lansoprazole-Delayed-Release-Capsules-USP-One-Each-For-Full-Prescription-And-OTC --Company Cleared to Market Prescription and OTC Generic Prevacid®-- Mon, 02 Oct 2017 06:56:00 -0400 http://lannett.investorroom.com/2017-10-02-Lannett-Receives-Two-FDA-Approvals-For-Lansoprazole-Delayed-Release-Capsules-USP-One-Each-For-Full-Prescription-And-OTC Lannett Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 5 mg/325 mg And 10 mg/325 mg http://lannett.investorroom.com/2017-09-27-Lannett-Receives-FDA-Approval-For-Oxycodone-And-Acetaminophen-Tablets-USP-5-mg-325-mg-And-10-mg-325-mg Wed, 27 Sep 2017 06:51:00 -0400 http://lannett.investorroom.com/2017-09-27-Lannett-Receives-FDA-Approval-For-Oxycodone-And-Acetaminophen-Tablets-USP-5-mg-325-mg-And-10-mg-325-mg Lannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg http://lannett.investorroom.com/2017-09-26-Lannett-Receives-Approval-For-Dexmethylphenidate-Hydrochloride-Tablets-2-5-mg-5-mg-And-10-mg Tue, 26 Sep 2017 06:53:00 -0400 http://lannett.investorroom.com/2017-09-26-Lannett-Receives-Approval-For-Dexmethylphenidate-Hydrochloride-Tablets-2-5-mg-5-mg-And-10-mg Lannett Announces Dismissal Of Class Action Lawsuit http://lannett.investorroom.com/2017-09-26-Lannett-Announces-Dismissal-Of-Class-Action-Lawsuit Tue, 26 Sep 2017 06:40:00 -0400 http://lannett.investorroom.com/2017-09-26-Lannett-Announces-Dismissal-Of-Class-Action-Lawsuit Lannett's Board Of Directors Initiates CEO Search http://lannett.investorroom.com/2017-09-25-Lannetts-Board-Of-Directors-Initiates-CEO-Search --CEO Arthur Bedrosian to Step Down Upon Naming of a Successor-- Mon, 25 Sep 2017 06:54:00 -0400 http://lannett.investorroom.com/2017-09-25-Lannetts-Board-Of-Directors-Initiates-CEO-Search